CHMP May 2026: Eight medicines recommended for approval and Wegovy goes oral
TL;DR
EMA’s CHMP in May 2026 recommended eight new medicines (including Jascayd for IPF/PPF), three hybrid medicines, and a positive biosimilar opinion for Vislyfa; it issued a negative opinion for Deqtynet, approved extensions of indications for several medicines, and withdrew initial authorisation applications for Orblid and Veblocema. The committee also endorsed Wegovy’s extension to a daily oral tablet and published accompanying updates and statistics (eight positive opinions on new medicines, one negative, and eighteen positive opinions on extensions in 2026).
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026 European Medicines Agency (EMA)
- Jascayd reinforces combination therapy shift in US pulmonary fibrosis treatment The Pharma Letter
- CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU Yahoo Finance Australia
- Medicines for lung disease and cancer are among EMA's eight new recommendations medwatch.com
- Nerandomilast Slowed FVC Decline, Improved Median Survival in Patients With IPF AJMC
Want the full story? Read the original reporting
Read on European Medicines Agency (EMA)